Allergy最新文献

{"title":"Baked milk diet is associated with improved quality of life and growth parameters in milk-allergic children.","authors":"Lydia Su Yin Wong, Marion Groetch, Henry T Bahnson, Elizabeth Strong, Anna Nowak-Wegrzyn, Hugh A Sampson","doi":"10.1111/all.16330","DOIUrl":"https://doi.org/10.1111/all.16330","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142386566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real‐world data from a large multi‐national UCARE study","authors":"R. Soegiharto, M. Alizadeh Aghdam, J. A. Sørensen, E. van Lindonk, F. Bulut Demir, N. Mohammad Porras, Y. Matsuo, L. Kiefer, A. C. Knulst, M. Maurer, C. Ritchie, M. Rudenko, E. Kocatürk, R. F. J. Criado, S. Gregoriou, T. Bobylev, A. Kleinheinz, S. Takahagi, M. Hide, A. M. Giménez‐Arnau, A. Salman, R. Oztas Kara, B. S. Dikicier, M. B. A. van Doorn, S. F. Thomsen, J. M. P. A. van den Reek, H. Röckmann","doi":"10.1111/all.16334","DOIUrl":"https://doi.org/10.1111/all.16334","url":null,"abstract":"BackgroundLong‐term data on the effectiveness and safety of omalizumab for chronic inducible urticaria (CIndU) in large populations are lacking.ObjectiveTo evaluate the effectiveness, safety, estimated omalizumab treatment duration and its predictors, as well as differences between CIndU subtypes, in a large long‐term CIndU cohort.MethodsA multinational multicenter study was conducted at 14 specialized urticaria centres (UCAREs), including all CIndU patients ever treated with omalizumab from 2009 until July 2022. Kaplan–Meier survival and regression analyses were performed.ResultsAcross 234 CIndU patients (55% female; mean age 37 years), 76% (<jats:italic>n</jats:italic> = 178) had standalone CIndU and 24% (<jats:italic>n</jats:italic> = 56) had predominant CIndU plus minor CSU, with an observation period up to 13 years. Most CIndU patients (73%, <jats:italic>n</jats:italic> = 145/200 with available data on response) had complete/good response to omalizumab treatment, without significant differences between CIndU subtypes. Sixty‐two (26%) patients discontinued omalizumab; due to well‐controlled disease (47%, <jats:italic>n</jats:italic> = 29), ineffectiveness (34%, <jats:italic>n</jats:italic> = 21), side effects (3%, <jats:italic>n</jats:italic> = 2), combination of ineffectiveness and side effects (3%, <jats:italic>n</jats:italic> = 2) and other reasons (13%, <jats:italic>n</jats:italic> = 8). The median estimated omalizumab treatment duration exceeded 5 years (54% drug survival at 5 years) and was mostly determined by well‐controlled disease. Higher age predicted a lower chance to discontinue omalizumab due to well‐controlled disease (HR 0.969, 95%CI 0.945–0.995). CIndU subtype and presence of minor CSU were not related to response and time until omalizumab discontinuation for any reason.ConclusionOmalizumab is highly effective and safe in CIndU patients, with long estimated treatment duration mainly reflecting long disease duration. Our data show omalizumab's high potential as treatment in any subtype of CIndU and support its clinical use for these patients.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"5 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142385481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The epithelial barrier theory and its associated diseases.","authors":"Na Sun, Ismail Ogulur, Yasutaka Mitamura, Duygu Yazici, Yagiz Pat, Xiangting Bu, Manru Li, Xueyi Zhu, Huseyn Babayev, Sena Ardicli, Ozge Ardicli, Paolo D'Avino, Ayca Kiykim, Milena Sokolowska, Willem van de Veen, Lukas Weidmann, Deniz Akdis, Banu Goker Ozdemir, Marie Charlotte Brüggen, Luc Biedermann, Alex Straumann, Andrea Kreienbühl, Emma Guttman-Yassky, Alexandra F Santos, Stefano Del Giacco, Claudia Traidl-Hoffmann, David J Jackson, De-Yun Wang, Antti Lauerma, Heimo Breiteneder, Luo Zhang, Liam O'Mahony, Oliver Pfaar, Robyn O'Hehir, Thomas Eiwegger, Wytske J Fokkens, Beatriz Cabanillas, Cevdet Ozdemir, Kistler Walter, Mahmut Bayik, Kari C Nadeau, Maria J Torres, Mübeccel Akdis, Marek Jutel, Ioana Agache, Cezmi A Akdis","doi":"10.1111/all.16318","DOIUrl":"https://doi.org/10.1111/all.16318","url":null,"abstract":"<p><p>The prevalence of many chronic noncommunicable diseases has been steadily rising over the past six decades. During this time, over 350,000 new chemical substances have been introduced to the lives of humans. In recent years, the epithelial barrier theory came to light explaining the growing prevalence and exacerbations of these diseases worldwide. It attributes their onset to a functionally impaired epithelial barrier triggered by the toxicity of the exposed substances, associated with microbial dysbiosis, immune system activation, and inflammation. Diseases encompassed by the epithelial barrier theory share common features such as an increased prevalence after the 1960s or 2000s that cannot (solely) be accounted for by the emergence of improved diagnostic methods. Other common traits include epithelial barrier defects, microbial dysbiosis with loss of commensals and colonization of opportunistic pathogens, and circulating inflammatory cells and cytokines. In addition, practically unrelated diseases that fulfill these criteria have started to emerge as multimorbidities during the last decades. Here, we provide a comprehensive overview of diseases encompassed by the epithelial barrier theory and discuss evidence and similarities for their epidemiology, genetic susceptibility, epithelial barrier dysfunction, microbial dysbiosis, and tissue inflammation.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.","authors":"Avner Reshef, Connie Hsu, Constance H Katelaris, Philip H Li, Markus Magerl, Keiko Yamagami, Mar Guilarte, Paul K Keith, Jonathan A Bernstein, John-Philip Lawo, Harsha Shetty, Maressa Pollen, Lolis Wieman, Tim J Craig","doi":"10.1111/all.16351","DOIUrl":"https://doi.org/10.1111/all.16351","url":null,"abstract":"<p><strong>Background: </strong>Hereditary angioedema (HAE) is a chronic, unpredictable disease. Long-term prophylactic treatments that offer durable efficacy, safety, and convenience are required to assist patients in achieving complete disease control, per international guidelines. We report an interim analysis of an ongoing phase 3 (VANGUARD) open-label extension (OLE) study evaluating the long-term safety and efficacy of garadacimab for HAE prophylaxis.</p><p><strong>Methods: </strong>Adults and adolescents aged ≥12 years with HAE previously participating in phase 2 and pivotal phase 3 (VANGUARD) studies were rolled over to an OLE, alongside newly enrolled patients. Patients received garadacimab 200 mg subcutaneously, once monthly for ≥12 months. The primary endpoint was treatment-emergent adverse events (TEAEs) in patients with C1 inhibitor deficiency/dysfunction.</p><p><strong>Results: </strong>At data cut-off (February 13, 2023; N = 161), median (interquartile range) exposure was 13.8 months (11.9-16.3). For the primary endpoint, 133/159 patients experienced ≥1 TEAE (524 events), equivalent to 0.23 events/administration and 2.84 events/patient-year. Garadacimab-related TEAEs (13% of patients, 52 events) were most commonly injection-site reactions (ISRs). No deaths occurred. One patient discontinued treatment due to garadacimab-related moderate ISR. Most TEAEs were mild/moderate; three events were serious (COVID-19, two events; abdominal HAE attack, one event) and not garadacimab related. No abnormal bleeding, thromboembolic, severe hypersensitivity, or anaphylactic events were observed. Mean HAE attack rate decreased by 95% from the run-in period; 60% of patients were attack-free. Almost all patients (93%) rated their response to garadacimab as \"good\" or \"excellent.\"</p><p><strong>Conclusion: </strong>Garadacimab has a favorable safety profile suitable for long-term use and provides durable protection against HAE attacks.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous reactions during Helicobacter pylori eradication therapy referred to an Allergy Department.","authors":"Celine Galleani, María José Peñalver, Ruth Barranco, Ismael García-Moguel, Jesús F Crespo, Beatriz Cabanillas","doi":"10.1111/all.16344","DOIUrl":"https://doi.org/10.1111/all.16344","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142374729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An algorithm for the diagnosis of betalactam allergy, 2024 update.","authors":"Inmaculada Doña, María Salas, Esther Moreno, Marta Ferrer, Cristobalina Mayorga, María José Torres","doi":"10.1111/all.16348","DOIUrl":"https://doi.org/10.1111/all.16348","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142374728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An algorithm for the diagnosis and treatment of nonsteroidal antiinflammatory drugs hypersensitivity, 2024 update.","authors":"Inmaculada Doña, Rocío Sáenz de Santa María, Esther María Moreno, Joan Bartra, María José Torres","doi":"10.1111/all.16349","DOIUrl":"https://doi.org/10.1111/all.16349","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ushering in a new era in food allergy management with EAACI guidelines.","authors":"Scott H Sicherer","doi":"10.1111/all.16350","DOIUrl":"https://doi.org/10.1111/all.16350","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142374730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Notch4 regulatory T cells and SARS-CoV-2 viremia shape COVID19 survival outcome.","authors":"Mehdi Benamar, Peggy S Lai, Ching-Ying Huang, Qian Chen, Fatma Betul Oktelik, Paola Contini, Muyun Wang, Daniel Okin, Elena Crestani, Jason Fong, Tsz Man Chan Fion, Merve Nida Gokbak, Hani Harb, Wanda Phipatanakul, Luca Marri, Chiara Vassallo, Andrea Guastalla, Minsik Kim, Hui-Yu Sui, Lorenzo Berra, Marcia B Goldberg, Claudia Angelini, Raffaele De Palma, Talal A Chatila","doi":"10.1111/all.16333","DOIUrl":"https://doi.org/10.1111/all.16333","url":null,"abstract":"<p><strong>Background: </strong>Immune dysregulation and SARS-CoV-2 plasma viremia have been implicated in fatal COVID-19 disease. However, how these two factors interact to shape disease outcomes is unclear.</p><p><strong>Methods: </strong>We carried out viral and immunological phenotyping on a prospective cohort of 280 patients with COVID-19 presenting to acute care hospitals in Boston, Massachusetts and Genoa, Italy between June 1, 2020 and February 8, 2022. Disease severity, mortality, plasma viremia, and immune dysregulation were assessed. A mouse model of lethal H1N1 influenza infection was used to analyze the therapeutic potential of Notch4 and pyroptosis inhibition in disease outcome.</p><p><strong>Results: </strong>Stratifying patients based on %Notch4⁺ Treg cells and/or the presence of plasma viremia identified four subgroups with different clinical trajectories and immune phenotypes. Patients with both high %Notch4⁺ Treg cells and viremia suffered the most disease severity and 90-day mortality compared to the other groups even after adjusting for baseline comorbidities. Increased Notch4 and plasma viremia impacted different arms of the immune response in SARS-CoV-2 infection. Increased Notch4 was associated with decreased Treg cell amphiregulin expression and suppressive function whereas plasma viremia was associated with increased monocyte cell pyroptosis. Combinatorial therapies using Notch4 blockade and pyroptosis inhibition induced stepwise protection against mortality in a mouse model of lethal H1N1 influenza infection.</p><p><strong>Conclusions: </strong>The clinical trajectory and survival outcome in hospitalized patients with COVID-19 is predicated on two cardinal factors in disease pathogenesis: viremia and Notch4⁺ Treg cells. Intervention strategies aimed at resetting the immune dysregulation in COVID-19 by antagonizing Notch4 and pyroptosis may be effective in severe cases of viral lung infection.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils","authors":"Kathleen M. Buchheit,&nbsp;Dominick Shaw,&nbsp;Geoffrey Chupp,&nbsp;Lauri Lehtimaki,&nbsp;Enrico Heffler,&nbsp;Tricia Finney-Hayward,&nbsp;James Zangrilli,&nbsp;Justin Kwiatek,&nbsp;Salman Siddiqui,&nbsp;Florence Roufosse,&nbsp;Andrew Thamboo,&nbsp;Nicholas West,&nbsp;Anna Vichiendilokkul,&nbsp;Peter W. Hellings,&nbsp;Anju Peters,&nbsp;Peter H. Howarth","doi":"10.1111/all.16303","DOIUrl":"10.1111/all.16303","url":null,"abstract":"<p>Interleukin (IL)-5 is the key cytokine in the maturation, activation, proliferation, migration and survival of eosinophils, which are key effector cells in many upper and lower airway diseases. Through its effects on eosinophils, IL-5 indirectly contributes to various pathophysiological processes including tissue damage, repair and remodelling. Understanding the importance of IL-5 in eosinophil-associated diseases led to the development of anti-IL-5 therapies, which provide clinical benefits across a range of conditions. However, recent evidence suggests that eosinophil-depletion alone may not account for all of the therapeutic effects of anti-IL-5 therapy and that IL-5 may also contribute to disease independently of its effects on eosinophils. Indeed, evidence from ex vivo studies and targeted therapy in vivo demonstrates that IL-5 and its inhibition affects a much broader range of cells beyond eosinophils, including epithelial cells, plasma cells, mast cells, basophils, neutrophils, type 2 innate lymphoid cells, T regulatory cells and fibroblasts. This review will provide an update on the evidence supporting the breadth of IL-5 biology relevant to disease pathogenesis beyond eosinophil-associated inflammation, where there is a need for additional insight, and the clinical implications of a more central role of IL-5 in type 2 inflammation.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":"79 10","pages":"2662-2679"},"PeriodicalIF":12.6,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16303","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142363562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}